Browsing Tag
Lupin Limited
41 posts
Lupin (NSE: LUPIN) signs licensing deal with Gan & Lee for Bofanglutide GLP-1 in India
Lupin signs exclusive India deal for Bofanglutide, a novel fortnightly GLP-1. Find out how it could reshape the obesity and diabetes market in 2026.
Lupin (NSE: LUPIN) secures CGT exclusivity for Risperidone LAI, launches first PrecisionSphere injectable in U.S.
Lupin Limited launches Risperidone injectable in the U.S. with 180-day CGT exclusivity, marking its entry into long-acting injectables via PrecisionSphere.
Lupin (NSE: LUPIN) goes big in the U.S.—$250m Coral Springs facility sparks investor buzz
Find out how Lupin’s $250 million Coral Springs manufacturing facility could redefine America’s respiratory drug security and boost U.S. pharma resilience.
Lupin deepens specialty push with VISUfarma acquisition: Can ophthalmology power its next European chapter?
Lupin acquires VISUfarma to expand into Europe’s ophthalmology market. Find out how this deal could reshape its specialty growth strategy.
Lupin launches first U.S. long-acting injectable from Nanomi—what does it mean for its specialty drug future?
Lupin’s risperidone injectable wins FDA approval with 180-day CGT exclusivity—marking the first major milestone for its Nanomi long-acting injectable platform.
Biologics race in Indian pharma: Can Glenmark’s AbbVie tie-up spark a broader innovation moment?
India’s biologics race heats up as Glenmark, Biocon, Sun Pharma, Dr. Reddy’s, and Lupin push beyond generics—see how each strategy stacks up.
Lupin Limited (NSE: LUPIN) gains on dual U.S. approvals for nasal spray and ophthalmic gel
Lupin Limited gains on U.S. nasal spray launch and FDA approval for ophthalmic gel. Find out how this could reshape its U.S. generics growth strategy.
Can Indian biosimilar makers dominate ophthalmology markets after Eylea patent expiries?
With Eylea patents expiring, Indian biosimilar makers are eyeing global ophthalmology markets. Find out who’s leading and what’s next.
Is Lupin doubling down on respiratory care? A look at its global inhalation drug pipeline
Lupin is expanding its respiratory care pipeline with global deals and inhaler innovation. Explore its strategy in COPD, asthma, and beyond.
Lupin signs China licensing deal for COPD drug Tiotropium DPI with Sino Universal Pharmaceuticals
Lupin enters China’s COPD market with a Tiotropium DPI licensing deal. Learn how this move shapes its global respiratory growth strategy.